Drugs /

modified folfirinox regimen

Back to Drugs List

Overview

NCI Definition [1]:
A modified, dose-adjusted regimen consisting of fluorouracil, irinotecan, leucovorin and oxaliplatin (FOLFIRINOX) used for the treatment of pancreatic cancer.

Clinical Trials

View Clinical Trials for modified folfirinox regimen

Modified folfirinox regimen has been investigated in 12 clinical trials, of which 12 are open and 0 are closed. Of the trials investigating modified folfirinox regimen, 3 are phase 1 (3 open), 7 are phase 2 (7 open), and 2 are phase 3 (2 open).

ATM Loss (germline), ATM Mutation (germline), and ATR Loss (germline) are the most frequent biomarker inclusion criteria for modified folfirinox regimen clinical trials.

Pancreatic adenocarcinoma, pancreatic ductal adenocarcinoma, and cancer are the most common diseases being investigated in modified folfirinox regimen clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Modified Folfirinox Regimen
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating modified folfirinox regimen and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
dose-attenuated folfirinox regimen, dose-adjusted folfirinox regimen, modified fluorouracil/irinotecan/leucovorin/oxaliplatin, modified fluorouracil/irinotecan/leucovorin/oxaliplatin regimen, mfolfirinox, mfolfirinox regimen, modified folfirinox
NCIT ID [1]:
C157345

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.